A Knuth
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
Feilchenfeldt J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano M, Grabsch H, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer 2015; 113:716-21.
Aug 27, 2015Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
Aug 27, 2015Br J Cancer 2015; 113:716-21
Feilchenfeldt J, Jochum Wolfram, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano Marco, Grabsch H I, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S
Uncommon case of brain metastasis in a patient with a history of heavy smoking.
Scharl M, Bode B, Rushing E, Knuth A, Rordorf T. Uncommon case of brain metastasis in a patient with a history of heavy smoking. Curr Oncol 2014; 21:e728-31.
Oct 1, 2014Uncommon case of brain metastasis in a patient with a history of heavy smoking.
Oct 1, 2014Curr Oncol 2014; 21:e728-31
Scharl Michael, Bode B, Rushing Elisabeth Jane, Knuth A, Rordorf Tamara
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Samaras P, Pestalozzi B, Knuth A, Renner C, Feilchenfeldt J, Heinrich S, Stenner-Liewen F, Haile S, Breitenstein S, Clavien P. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Ann Surg Oncol 2011; 18:1924-31.
Jan 5, 2011Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Jan 5, 2011Ann Surg Oncol 2011; 18:1924-31
Samaras Panagiotis, Pestalozzi B C, Knuth A, Renner C, Feilchenfeldt J, Heinrich S, Stenner-Liewen F, Haile Sarah, Breitenstein S, Clavien P A
Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
Petrausch U, Renner C, Mischo A, Hany T, Knuth A, Soyka J, Veit-Haibach P, Haile S, Samaras P, Schäefer N. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010; 21:1694-8.
Feb 5, 2010Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
Feb 5, 2010Ann Oncol 2010; 21:1694-8
Petrausch U, Renner C, Mischo A, Hany T F, Knuth A, Soyka J D, Veit-Haibach P, Haile Sarah, Samaras P, Schäefer N G
MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome
Tinguely M, Knuth A, Moch H, Probst-Hensch N, Renner C, Maurer R, Dommann-Scherrer C, Schmid U, Bittermann A, Cogliatti S, Curioni Fontecedro A, Rousson V, Korol D, Lopes B, Knights A, Jenni B, Zippelius A. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer science 2008; 99:720-5.
Apr 1, 2008MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome
Apr 1, 2008Cancer science 2008; 99:720-5
Tinguely M, Knuth A, Moch H, Probst-Hensch N M, Renner C, Maurer R, Dommann-Scherrer C, Schmid U, Bittermann A G, Cogliatti Sergio B., Curioni Fontecedro A, Rousson V, Korol D, Lopes B, Knights A, Jenni B, Zippelius A